AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services proposal to require federal minimum staffing levels in nursing homes.

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services’ list of the first 10 drugs to be negotiated for lower prices by Medicare.

List prices for the 25 brand-name drugs with the highest total Medicare Part D spending in 2021 have increased by an average of 226%—or more than tripled—since they first entered the market, a new report from AARP’s Public Policy Institute shows.

AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services’ final implementation guidance of the Medicare Drug Price Negotiation Program.

AARP CEO Jo Ann Jenkins issued the following statement in response to the Medicare and Social Security Trustees’ reports released today.